Omadacycline (PTK 0796), a first-in-class orally active aminomethylcyclineantibacterial, is a member of thetetracyclineclass ofantibiotics. Omadacycline acts through the inhibition ofbacterialprotein synthesisby binding to the 30S ribosomal subunit. Omadacycline possesses broad-spectrum antibacterial activity against aerobic and anaerobic Gram-positive and Gram-negative bacteria, as well as atypical bacteria. Omadacycline can be used for the research of acutebacterialskin and skin-structure infections, community-acquired pneumonia, and urinary tract infections^[1][2][3][4].

Omadacycline displays activity against methicillin-resistantStaphylococcus aureus(MRSA), vancomycin-resistantEnterococcus(VRE), beta-hemolytic streptococci, penicillin-resistantStreptococcus pneumonia(PRSP) andHaemophilus influenzae (H. influenzae), with MIC₉₀s of 1.0, 0.25, 0.5, 0.25 and 2.0 μg/mL respectively^[2].
Omadacycline is active against strains expressing tetracycline and other antibiotics resistance by ribosomal protection and active tetracycline efflux^[2].

Omadacycline (0.11-18 mg/kg; a single i.v.) exhibits efficacy againstStreptococcus pneumonia,Escherichia coli, andStaphylococcus aureusin mice systemic infection model, with ED₅₀s ranging from 0.30 mg/kg to 3.39 mg/kg^[2].

556.65

C₂₉H₄₀N₄O₇

389139-89-3

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.